A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824002015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846159000338432000 |
|---|---|
| author | J. Kaczmar K. Papadopoulos G. Ansstas A. Birnbaum J. Mehnert O. Hamid B. Hughes G. Rabinowits A. Wei M. Yushak J. Mani F. Fang J. Wang G. Kroog M. Salvati I. Lowy M. Fury N.J. Lakhani |
| author_facet | J. Kaczmar K. Papadopoulos G. Ansstas A. Birnbaum J. Mehnert O. Hamid B. Hughes G. Rabinowits A. Wei M. Yushak J. Mani F. Fang J. Wang G. Kroog M. Salvati I. Lowy M. Fury N.J. Lakhani |
| author_sort | J. Kaczmar |
| collection | DOAJ |
| format | Article |
| id | doaj-art-00ea4c444df04784a5625b1f58c42fe7 |
| institution | Kabale University |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-00ea4c444df04784a5625b1f58c42fe72024-11-24T04:15:16ZengElsevierEJC Skin Cancer2772-61182024-01-012100213A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinomaJ. Kaczmar0K. Papadopoulos1G. Ansstas2A. Birnbaum3J. Mehnert4O. Hamid5B. Hughes6G. Rabinowits7A. Wei8M. Yushak9J. Mani10F. Fang11J. Wang12G. Kroog13M. Salvati14I. Lowy15M. Fury16N.J. Lakhani17MUSC Hollings Cancer Center, North Charleston, United States of AmericaSTART, San Antonio, United States of AmericaWashington University School of Medicine, St. Louis, United States of AmericaRhode Island Hospital, Providence, United States of AmericaRutgers Cancer Institute of New Jersey, New Brunswick, United States of AmericaThe Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, United States of AmericaRoyal Brisbane and Women's Hospital and University of Queensland, Brisbane, AustraliaMiami Cancer Institute, Miami, United States of AmericaColumbia University, New York, United States of AmericaDepartment of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaRegeneron Pharmaceuticals, Inc., Tarrytown, United States of AmericaSTART Midwest, Grand Rapids, United States of Americahttp://www.sciencedirect.com/science/article/pii/S2772611824002015 |
| spellingShingle | J. Kaczmar K. Papadopoulos G. Ansstas A. Birnbaum J. Mehnert O. Hamid B. Hughes G. Rabinowits A. Wei M. Yushak J. Mani F. Fang J. Wang G. Kroog M. Salvati I. Lowy M. Fury N.J. Lakhani A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma EJC Skin Cancer |
| title | A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma |
| title_full | A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma |
| title_fullStr | A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma |
| title_full_unstemmed | A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma |
| title_short | A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma |
| title_sort | phase 1 study of fianlimab in combination with cemiplimab in patients with anti pd 1 l1 experienced cutaneous squamous cell carcinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824002015 |
| work_keys_str_mv | AT jkaczmar aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT kpapadopoulos aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT gansstas aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT abirnbaum aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jmehnert aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT ohamid aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT bhughes aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT grabinowits aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT awei aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT myushak aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jmani aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT ffang aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jwang aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT gkroog aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT msalvati aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT ilowy aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT mfury aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT njlakhani aphase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jkaczmar phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT kpapadopoulos phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT gansstas phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT abirnbaum phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jmehnert phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT ohamid phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT bhughes phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT grabinowits phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT awei phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT myushak phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jmani phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT ffang phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT jwang phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT gkroog phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT msalvati phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT ilowy phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT mfury phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma AT njlakhani phase1studyoffianlimabincombinationwithcemiplimabinpatientswithantipd1l1experiencedcutaneoussquamouscellcarcinoma |